CSF2 and lung carcinoma: The clinical use of GM-CSF as an adjuvant has been evaluated for the treatment of cancer such as prostate, skin, breast, and lung cancer in an attempt to boost the antitumor immune response by increasing the efficiency of antigen presentation by dendritic cells and consequently improving T-cell activation [12,13,14].